Co-infection with Influenza A and COVID-19

Venu Madhav Konala¹, Sreedhar Adapa², Vijay Gayam³, Srikanth Naramala⁴, Subba Rao Duggubati⁵, Chetan Brahma Kammari⁶, Avantika Chenna⁷
¹Department of Internal Medicine, Division of Medical Oncology, Ashland Bellefonte Cancer Center, Ashland, KY, USA
²Department of Internal Medicine, Division of Nephrology, Adventist Medical Center, Hanford, CA, USA
³Department of Medicine, Interfaith Medical Center, Brooklyn, NY, USA
⁴Department of Internal Medicine, Division of Rheumatology, Adventist Medical Center, Hanford, CA, USA
⁵Wise Health System, Decatur, TX, USA
⁶Internal Medicine, Cape Fear Valley Hospital, Fayetteville, NC, USA
⁷Phoe Putney Memorial Hospital, Medical College of Georgia, Albany, GA, USA

How to cite this article: Konala VM, Adapa S, Gayam V, Naramala S, Duggubati SR, Kammari CB, Chenna A. Co-infection with influenza A and COVID-19. EJCRIM 2020;7: doi:10.12890/2020_001656.

ABSTRACT
COVID-19, also called severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2), originated in Wuhan, China. It has caused significant morbidity and mortality worldwide and has been declared a global pandemic by the WHO. Influenza occurs mainly during the winter, with the burden of disease determined by several factors, including the effectiveness of the vaccine that season, the characteristics of the circulating viruses, and how long the season lasts. We describe the case of a 66-year-old woman who was diagnosed with influenza A and COVID-19 co-infection.

LEARNING POINTS
• COVID-19 can co-occur with other viral infections.
• Some of these co-infections have active treatments, while supportive treatment is the mainstay of treatment for others.

KEYWORDS
Coronavirus, COVID-19, influenza, acute respiratory distress syndrome

INTRODUCTION
COVID-19, also called severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2), originated in Wuhan, China. It has caused significant morbidity and mortality worldwide and has been declared a global pandemic by the WHO [1]. The USA currently has the highest number of positive cases and the highest number of deaths globally as the disease continues to spread across the country [2]. We describe the case of a 66-year-old woman with a diagnosis of influenza A and COVID-19 co-infection.

CASE DESCRIPTION
A 66-year-old African-American woman was referred by her primary care provider with a syncopal episode. She complained of fever with a maximum temperature of 38.9°C as well as a non-productive cough, shortness of breath and decreased appetite 3 days before presentation. Her medical history was significant for ischaemic cardiomyopathy, type 2 diabetes mellitus, hypertension, coronary artery disease, and chronic kidney disease with a baseline creatinine of 1.3. Her surgical history was significant for right carotid endarterectomy in 2018 and placement of an automated internal cardioverter defibrillator in 2012. Patient characteristics are summarized in Table 1.
Her vital signs on presentation were blood pressure of 140/70 mmHg, heart rate of 81 bpm, respiratory rate of 19 bpm, temperature of 37.8°C, and an oxygen saturation of 91% on a nasal cannula with a flow rate of 2 l/min. Physical examination was significant for obesity but no acute distress, and coarse breath sounds bilaterally on auscultation. The rest of the examination was unremarkable. The patient’s laboratory test results are given in Table 2. The influenza A test was positive. The nasopharyngeal swab was sent for COVID-19 testing, which was reported positive a couple of days later. A chest x-ray showed a right lower lobe infiltrate (Fig. 1).

| Characteristics                          | Patient information                                      |
|------------------------------------------|----------------------------------------------------------|
| Symptoms                                 | Cough, shortness of breath, fever                         |
| Smoking                                  | Ex-smoker, quit in 2004                                   |
| Co-morbidities                           | Hypertension, Diabetes, Chronic kidney disease stage 3, Congestive heart failure, Coronary artery disease |
| Patient on ACE inhibitors or angiotensin receptor blockers | Losartan 25 mg                                             |
| Diuretics                                | Patient not on any diuretics                              |
| Non-steroidal anti-inflammatory drugs (NSAIDs) | Patient not on any NSAIDs                               |

| Laboratory parameter                   | Patient values                                           |
|-----------------------------------------|----------------------------------------------------------|
| Haemoglobin                             | 13.8 g/dl                                                |
| White cell count                        | 6,100/mm³                                                |
| Lymphocyte count                        | 1,000/mm³                                                |
| Platelet count                          | 180K/mm³                                                 |
| Sodium                                  | 140 mmol/l                                               |
| Potassium                                | 4.3 mmol/l                                               |
| Bicarbonate                             | 28 mmol/l                                                 |
| Blood urea nitrogen                     | 26 mg/dl                                                  |
| Serum creatinine                        | 1.56 mg/dl                                                |
| Creatinine phosphokinase                | 89 U/l                                                   |
| Urine analysis                          | No protein, No RBC casts                                 |
| Urine protein creatinine ratio          | 100/74                                                   |
| Influenza A                             | Positive                                                  |
| COVID-19                                 | Positive                                                  |

Table 1. Patient characteristics
Table 2. Laboratory test results

Figure 1. Chest x-ray showing right lower lobe infiltrate
The patient was initially admitted to the medical department and was started on Tamiflu 30 mg by mouth twice a day for 5 days, along with azithromycin and ceftriaxone for treatment of community-acquired pneumonia, and hydroxychloroquine for suspected COVID-19 as per hospital protocol. The patient was started on intravenous (IV) normal saline for acute kidney injury with improvement in renal function. However, the patient’s clinical condition deteriorated with hypoxia despite the use of high-flow oxygen and she was transferred to the intensive care unit when the initial ABG showed a pH of 7.3, PO$_2$ of 59 mmHg and PCO$_2$ of 45 mmHg despite the fact that she was on high-flow oxygen via a nasal cannula at 40 l/min. Subsequently, the patient was intubated and ventilated. Her losartan was stopped, while IV fluids were continued. However, renal deterioration progressed so IV fluids were also discontinued and the patient was started on diuretics. Nevertheless, renal failure continued to worsen and as the patient was found to be dehydrated, diuretics were stopped. Urine output subsequently increased, and the creatinine improved to 1.5, closer to the patient’s baseline value. The patient continues to be ventilator-dependent with minimal settings with an Fio2 of 30% with a plan for tracheostomy and percutaneous gastrostomy tube placement.

**DISCUSSION**

COVID-19 can initially present with minor symptoms such as fever with or without chills, dry cough, shortness of breath, fatigue, muscle aches, sore throat, confusion, headache and rhinorrhea. The lung is the main organ affected, which can result in respiratory failure. The disease can also present with atypical symptoms such as nausea, vomiting and diarrhoea [1]. Influenza in the USA occurs mainly during winter, and the burden of disease is determined by several factors, including the effectiveness of the vaccine that season, the characteristics of the circulating viruses, and how long the season lasts. According to CDC estimates, during the 2018–2019 season symptomatic influenza occurred in approximately 35 million patients, which resulted in approximately 16 million hospital visits and approximately 500,000 hospitalizations with 34,000 deaths [3]. The most common symptoms of influenza are fever, cough, shortness of breath, fatigue, headache, myalgia and arthralgia, similar to those of COVID-19.

COVID-19 can simultaneously present with other infections such as influenza, and it can be hard to distinguish the symptoms of the two conditions from each other. However, there are differences and these are summarized in Table 3 [1]. A study by Xing et al. analysed common respiratory pathogens presenting as co-infections with COVID-19 from Quingdao and Wuhan. This report identified IgM antibodies to at least one respiratory pathogen in 80% and 2.6% of the patients from Quingdao and Wuhan, respectively. Influenza A, influenza B, followed by *Mycoplasma* and *Legionella*, were the most common respiratory pathogens detected [4].

|                           | Influenza                              | COVID-19                               |
|---------------------------|----------------------------------------|----------------------------------------|
| **Asymptomatic or symptomatic** | Patients can be asymptomatic due to herd immunity | Most patients develop symptoms within 2 days of infection |
| **Viral shedding** | 5–10 days                             | Up to 14 days or even longer          |
| **Severity of illness**   | Majority of infections are mild to moderate | Severe illness can occur               |
| **Mortality**             | Less than 1%                          | 3–4%                                  |
| **Vaccines**              | Vaccines available; efficacy varies from season to season | No vaccine available, clinical trials in progress |
| **Treatment**             | Oseltamivir                            | No treatment available, clinical trials in progress |
|                           | Zanamivir                              |                                        |
|                           | Peramivir                              |                                        |
|                           | Baloxavir                              |                                        |
| **Acute respiratory distress syndrome** | Less common                           | More common                           |

Table 3. Differences between influenza and COVID-19

In a study from Wuhan, five of 115 patients were co-infected with COVID-19 and influenza. Most of these patients presented with fever, cough and shortness of breath. All of the co-infected patients presented with pharyngeal pain. Only one of the co-infected patients developed acute respiratory distress syndrome and required non-invasive ventilation.
Acute liver injury occurred in three of the patients and diarrhoea in two. All patients were treated with oseltamivir, antibiotics and supplemental oxygen, and three of the patients required steroids [5]. Many novel treatments for COVID-19 are under investigation, and although some of these options are already being used in clinical practice (as in our patient), none are currently approved for routine use. Many centres have started incorporating treatment with hydroxychloroquine and azithromycin based on a small study by Gautret et al., where the combination decreased the duration of viral shedding and increased elimination of the virus [6].

We currently do not know the impact on patients of co-infection with both influenza and COVID-19, or whether influenza alters clinical outcomes in patients already infected with COVID-19.

CONCLUSION

Influenza and COVID-19 co-infection can occur in patients and can present with similar symptoms. It is essential to recognize the co-infections as some can be treated with antibiotics and antivirals. We already have treatments for influenza, but while multiple drugs are being investigated for COVID-19, none have been approved for treatment so far. We encourage patients to be vaccinated against pathogens causing respiratory infections to reduce the risk of co-infection.

REFERENCES

1. Balla M, Merugu GP, Patel M, Koduri NM, Gayam V, Adapa S, et al. COVID-19, modern pandemic: a systematic review from a front-line health care providers’ perspective. J Clin Med Res 2020;12(4):215–229.
2. John Hopkins University of Medicine Coronavirus Resource Center. Available from https://coronavirus.jhu.edu/map.html (accessed 11 April 2020).
3. Centers for Disease Control and Prevention. Influenza (Flu). Available from https://www.cdc.gov/flu/about/burden/index.html (accessed 11 April 2020).
4. Xing Q, Li GJ, Xing YH, Chen T, Li WJ, Ni W, et al. Precautions are needed for COVID-19 patients with coinfection of common respiratory pathogens. Available from http://dx.doi.org/10.2139/ssrn.3550013 (accessed 17 April 2020).
5. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol 2020 Mar 20. doi: 10.1002/jmv.25781 [Epub ahead of print].
6. Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949 [Epub ahead of print].